Company profile
Vaximm company profile
Vaximm is focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinical trials in 2011.
Business identity
- Website
- https://vaximm.com
- Contact email
- [email protected]
- Phone number
- + 49-0621-83-596-8750
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 1-10 employees
- Revenue range
- $0-$1M
- Founded
- 2008-01-01, Year
Headquarters
- Headquarters
- Breíl, Grisons, Switzerland
- Postal code
- 4057
- Country code
- CH
- Continent
- Europe